Skip to main content
$172.06Today:- (-)1Y +106.92%

As of Oct 26, 2026 close

Market cap
$268.41B
P/E (TTM)
25.70
Forward P/E
20.59
Dividend yield
1.87%
52-week range
$81.02$212.71
Volume (live)
-
Avg. volume (3M)
2.85M

AstraZeneca (AZN) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), AstraZeneca generated $14.57B of operating cash flow and spent $5.91B on capital expenditures. That left free cash flow of $8.67B, down 12.8% from $9.94B a year earlier, or 14.8% of revenue. It returned $5.49B to shareholders through $4.97B in dividends and $521.00M in share buybacks.

AstraZeneca Cash Flow Statement Analysis

Values in billions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for AstraZeneca PLC (AZN) - Annual data in billions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
Operating Activities
Net Income12.408.696.902.50-0.273.921.551.992.23
Depreciation & Amortization5.496.694.935.486.533.153.763.753.04
Deferred Income Tax0.000.000.00-0.62-0.62-0.28-0.260.000.00
Stock Based Compensation0.370.040.580.030.050.280.260.000.00
Change in Working Capital-1.14-0.890.303.762.020.36-0.35-0.64-0.05
Change in Accounts Receivable-1.73-1.62-1.43-1.35-0.96-0.74-0.90-0.520.08
Change in Inventory-0.76-0.13-0.673.941.58-0.62-0.32-0.01-0.55
Change in Accounts Payable1.350.861.431.171.410.740.900.000.00
Change in Other Working Capital1.821.530.97-0.180.440.98-0.03-0.100.42
Other Operating Activities1.820.13-2.37-0.31-0.58-2.63-2.00-2.49-1.64
Net Cash from Operating Activities14.5811.8610.359.815.964.802.972.623.58
Investing Activities
Capital Expenditures-5.91-1.92-3.78-1.09-1.09-2.61-2.46-1.37-1.62
Acquisitions-1.24-3.78-1.18-0.82-9.91-0.83-0.78-0.54-1.96
Purchases of Investments-0.23-0.25-0.14-0.07-0.28-0.12-0.01-0.10-0.44
Sales/Maturities of Investments0.130.090.130.040.792.130.210.430.07
Other Investing Activities0.420.37-1.52-0.27-0.061.142.392.541.62
Net Cash from Investing Activities-6.81-7.98-4.06-2.96-11.06-0.29-0.660.96-2.33
Financing Activities
Debt Repayment-2.03-4.65-0.97-1.27-9.521.65-1.191.470.22
Common Stock Issued-0.480.040.030.030.030.033.530.030.04
Common Stock Repurchased-0.52-0.080.000.000.000.000.000.000.00
Dividends Paid-4.97-4.63-4.48-4.36-3.86-3.57-3.59-3.48-3.52
Other Financing Activities-0.07-0.84-1.15-1.05-0.18-0.313.01-0.030.32
Net Cash from Financing Activities-7.54-4.00-6.57-6.823.65-2.20-1.77-2.04-2.94
Summary
Effect of Forex Changes on Cash0.05-0.09-0.06-0.08-0.060.010.01-0.04-0.07
Net Change in Cash0.22-0.21-0.35-0.06-1.512.320.551.50-1.75
Cash at Beginning of Period5.435.645.986.047.555.224.673.174.92
Cash at End of Period5.705.435.645.986.047.555.224.673.17
Free Cash Flow8.679.946.578.724.872.190.511.251.96
Supplemental Disclosures
Interest Paid1.321.311.080.850.72----
Income Taxes Paid2.852.752.371.621.74----

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About AstraZeneca Cash Flow

What is AstraZeneca's free cash flow?

AstraZeneca generated free cash flow of $8.67B in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of $14.57B minus $5.91B of capital expenditures. That was down 12.8% from $9.94B a year earlier. Free cash flow equaled 14.8% of revenue.

How much does AstraZeneca spend on capital expenditures?

AstraZeneca spent $5.91B on capital expenditures in fiscal 2025, compared with $1.92B a year earlier. That equals 40.5% of operating cash flow.

Does AstraZeneca pay dividends or buy back shares?

Yes. In fiscal 2025 AstraZeneca returned $4.97B in dividends and $521.00M in share buybacks to shareholders, according to its cash flow statement.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition